Evidence map›Paper›PMID 30458964›Full record

ArticleAtherosclerosis2019

Coronary heart disease mortality in severe vs. non-severe familial hypercholesterolaemia in the Simon Broome Register.

Steve E Humphries, Jackie A Cooper, Nigel Capps, Paul N Durrington, Ben Jones, Ian F W McDowell, Handrean Soran, Andrew H W Neil, Simon Broome Familial Hyperlipidaemia Register Group

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Atherosclerosis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Past, Present, and Future of Familial Hypercholesterolemia Management.Methodist DeBakey cardiovascular journal · 2021
    Review
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Steve E HumphriesCentre for Cardiovascular Genetics, Institute of Cardiovascular Science, University College London, University Street, London, WC1E 6JJ, UK. Electronic address: steve.humphries@ucl.ac.uk.
Jackie A CooperCentre for Cardiovascular Genetics, Institute of Cardiovascular Science, University College London, University Street, London, WC1E 6JJ, UK.
Nigel CappsDepartment of Clinical Biochemistry, The Shrewsbury and Telford Hospital NHS Trust, Princess Royal Hospital, Telford, UK.
Paul N DurringtonCardiovascular Research Group, School of Clinical and Laboratory Sciences, University of Manchester, Manchester, UK.
Ben JonesSection of Investigative Medicine, Imperial College London, London, UK.
Ian F W McDowellDepartment of Medical Biochemistry and Immunology, University Hospital of Wales, Cardiff, UK.
Handrean SoranUniversity Department of Medicine, Manchester University Hospitals NHS Foundation Trust, Manchester, UK.
Andrew H W NeilWolfson College, University of Oxford, Oxford, UK.
Simon Broome Familial Hyperlipidaemia Register Group

Funding

British Heart Foundation RG008/08British Heart Foundation RG3008Medical Research Council MR/K023667/1
6 · The paper itself

Abstract

BACKGROUND AND

aimsThe International Atherosclerosis Society (IAS) has proposed that patients with "severe" FH (SFH) would warrant early and more aggressive cholesterol-lowering treatment such as with PCSK9 inhibitors. SFH is diagnosed if LDL-cholesterol (LDLC) > 10 mmol/L, or LDLC >8.0 mmol/L plus one high-risk feature, or LDLC >5 mmol/L plus two high-risk features. Here we compare CHD mortality in SFH and non-SFH (NSFH) patients in the UK prospective Simon Broome Register since 1991, when statin use became routine.

methods2929 definite or possible PFH patients (51% women) aged 20-79 years were recruited from 21 UK lipid clinics and followed prospectively between 1992 and 2016. The excess CHD standardised mortality ratio (SMR) compared to the England and Wales population was calculated (with 95% confidence intervals).

results1982 (67.7%) patients met the SFH definition. Compared to the non-SFH, significantly (p < 0.001) more SFH patients had diagnosed CHD at baseline (24.6% vs. 17.5%), were current smokers (21.9% vs 10.2%) and had a BMI > 30 kg/m

conclusionsCHD mortality remains elevated in treated FH, especially for SFH, emphasising the importance of optimal lipid-lowering and management of other risk factors.

Indexed as

AdultAgedBiomarkersCholesterol, LDLCoronary DiseaseFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHyperlipoproteinemia Type IIMaleMiddle AgedPCSK9 InhibitorsPrognosisProprotein Convertase 9Prospective StudiesRegistriesBiomarkersCholesterol, LDLHydroxymethylglutaryl-CoA Reductase InhibitorsPCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9Serine EndopeptidasesCoronary mortalitySevere heterozygous familial hypercholesterolemia

Identifiers

PMID30458964
PMCPMC6403443

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.